These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 18000659)
1. The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition. Rakhit A; Pantze MP; Fettner S; Jones HM; Charoin JE; Riek M; Lum BL; Hamilton M Eur J Clin Pharmacol; 2008 Jan; 64(1):31-41. PubMed ID: 18000659 [TBL] [Abstract][Full Text] [Related]
2. Preclinical assessment of the interactions between the antiretroviral drugs, ritonavir and efavirenz, and the tyrosine kinase inhibitor erlotinib. Deeken JF; Beumer JH; Anders NM; Wanjiku T; Rusnak M; Rudek MA Cancer Chemother Pharmacol; 2015 Oct; 76(4):813-9. PubMed ID: 26330331 [TBL] [Abstract][Full Text] [Related]
3. Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design matters. Gidal BE; Maganti R; Laurenza A; Yang H; Verbel DA; Schuck E; Ferry J Epilepsy Res; 2017 Aug; 134():41-48. PubMed ID: 28535410 [TBL] [Abstract][Full Text] [Related]
4. Relative contributions of the major human CYP450 to the metabolism of icotinib and its implication in prediction of drug-drug interaction between icotinib and CYP3A4 inhibitors/inducers using physiologically based pharmacokinetic modeling. Chen J; Liu D; Zheng X; Zhao Q; Jiang J; Hu P Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):857-68. PubMed ID: 25850339 [TBL] [Abstract][Full Text] [Related]
5. Prediction of crizotinib-midazolam interaction using the Simcyp population-based simulator: comparison of CYP3A time-dependent inhibition between human liver microsomes versus hepatocytes. Mao J; Johnson TR; Shen Z; Yamazaki S Drug Metab Dispos; 2013 Feb; 41(2):343-52. PubMed ID: 23129213 [TBL] [Abstract][Full Text] [Related]
6. The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers. Shi JG; Chen X; Emm T; Scherle PA; McGee RF; Lo Y; Landman RR; McKeever EG; Punwani NG; Williams WV; Yeleswaram S J Clin Pharmacol; 2012 Jun; 52(6):809-18. PubMed ID: 21602517 [TBL] [Abstract][Full Text] [Related]
7. Inhibitory effect of ketoconazole on the pharmacokinetics of a multireceptor tyrosine kinase inhibitor BMS-690514 in healthy participants: assessing the mechanism of the interaction with physiologically-based pharmacokinetic simulations. Yang Z; Vakkalagadda B; Shen G; Ahlers CM; Has T; Christopher LJ; Kurland JF; Roongta V; Masson E; Zhang S J Clin Pharmacol; 2013 Feb; 53(2):217-27. PubMed ID: 23436267 [TBL] [Abstract][Full Text] [Related]
8. In vitro-in vivo extrapolation of zolpidem as a perpetrator of metabolic interactions involving CYP3A. Polasek TM; Sadagopal JS; Elliot DJ; Miners JO Eur J Clin Pharmacol; 2010 Mar; 66(3):275-83. PubMed ID: 20012430 [TBL] [Abstract][Full Text] [Related]
9. In Silico Predictions and In Vivo Results of Drug-Drug Interactions by Ketoconazole and Verapamil on AZD1305, a Combined Ion Channel Blocker and a Sensitive CYP3A4 Substrate. Johansson S; Löfberg B; Aunes M; Lunde H; Frison L; Edvardsson N; Cullberg M Clin Pharmacol Drug Dev; 2016 Sep; 5(5):364-73. PubMed ID: 27627192 [TBL] [Abstract][Full Text] [Related]
10. Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia. Prakash C; Fan B; Ke A; Le K; Yang H Cancer Chemother Pharmacol; 2020 Nov; 86(5):619-632. PubMed ID: 32978634 [TBL] [Abstract][Full Text] [Related]
11. The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects. Hamilton M; Wolf JL; Drolet DW; Fettner SH; Rakhit AK; Witt K; Lum BL Cancer Chemother Pharmacol; 2014 Mar; 73(3):613-21. PubMed ID: 24474302 [TBL] [Abstract][Full Text] [Related]
12. Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4. Brown HS; Galetin A; Hallifax D; Houston JB Clin Pharmacokinet; 2006; 45(10):1035-50. PubMed ID: 16984215 [TBL] [Abstract][Full Text] [Related]
13. Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interaction. Youdim KA; Zayed A; Dickins M; Phipps A; Griffiths M; Darekar A; Hyland R; Fahmi O; Hurst S; Plowchalk DR; Cook J; Guo F; Obach RS Br J Clin Pharmacol; 2008 May; 65(5):680-92. PubMed ID: 18279465 [TBL] [Abstract][Full Text] [Related]
14. Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects. Shoaf SE; Bricmont P; Mallikaarjun S Br J Clin Pharmacol; 2012 Apr; 73(4):579-87. PubMed ID: 21988334 [TBL] [Abstract][Full Text] [Related]
15. CYP3A4-based drug-drug interaction: CYP3A4 substrates' pharmacokinetic properties and ketoconazole dose regimen effect. Boulenc X; Nicolas O; Hermabessière S; Zobouyan I; Martin V; Donazzolo Y; Ollier C Eur J Drug Metab Pharmacokinet; 2016 Feb; 41(1):45-54. PubMed ID: 25374256 [TBL] [Abstract][Full Text] [Related]
16. Use of transgenic mouse models to understand the oral disposition and drug-drug interaction potential of cobimetinib, a MEK inhibitor. Choo EF; Woolsey S; DeMent K; Ly J; Messick K; Qin A; Takahashi R Drug Metab Dispos; 2015 Jun; 43(6):864-9. PubMed ID: 25813936 [TBL] [Abstract][Full Text] [Related]
17. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Li J; Zhao M; He P; Hidalgo M; Baker SD Clin Cancer Res; 2007 Jun; 13(12):3731-7. PubMed ID: 17575239 [TBL] [Abstract][Full Text] [Related]
18. Variation in the Response of Clozapine Biotransformation Pathways in Human Hepatic Microsomes to CYP1A2- and CYP3A4-selective Inhibitors. Murray M; Zhang WV; Edwards RJ Basic Clin Pharmacol Toxicol; 2018 Apr; 122(4):388-395. PubMed ID: 29155491 [TBL] [Abstract][Full Text] [Related]
19. Effect of cytochrome P450 3A4 inhibitor ketoconazole on risperidone pharmacokinetics in healthy volunteers. Mahatthanatrakul W; Sriwiriyajan S; Ridtitid W; Boonleang J; Wongnawa M; Rujimamahasan N; Pipatrattanaseree W J Clin Pharm Ther; 2012 Apr; 37(2):221-5. PubMed ID: 21518375 [TBL] [Abstract][Full Text] [Related]
20. Inhibition and stimulation of intestinal and hepatic CYP3A activity: studies in humanized CYP3A4 transgenic mice using triazolam. van Waterschoot RA; Rooswinkel RW; Sparidans RW; van Herwaarden AE; Beijnen JH; Schinkel AH Drug Metab Dispos; 2009 Dec; 37(12):2305-13. PubMed ID: 19752211 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]